Welcome to our dedicated page for DNAA news (Ticker: DNAA), a resource for investors and traders seeking the latest updates and insights on DNAA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DNAA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DNAA's position in the market.
Akili Interactive is set to go public through a merger with Social Capital Suvretta Holdings Corp. I (DNAA). This transaction, valued at up to $1 billion, aims to launch Akili’s FDA-cleared digital therapeutic, EndeavorRx®, designed for pediatric ADHD. The merger is expected to provide approximately $412 million in cash proceeds and strengthen Akili’s pipeline for treating various cognitive impairments. Following the merger, Akili will continue expanding its digital medicine platform focused on cognitive health. The transaction is anticipated to close in mid-2022.
Social Capital Suvretta Holdings Corp. I has priced its upsized initial public offering of 22,000,000 Class A ordinary shares at $10.00 per share, set to trade under the ticker DNAA on the Nasdaq from June 30, 2021. The company, led by Chamath Palihapitiya and Kishen Mehta, is a blank check firm focusing on mergers in the biotechnology sector, particularly within neurology. Underwriters have a 45-day option to purchase an additional 3,300,000 shares.